Drug intelligence / Profile preview

TCB190

Development stage: Unknown
Lead developer: FibroBiologics

Overview

**TCB190** is an investigational cell therapy developed by FibroBiologics for the treatment of certain cancers. It is referenced in SEC filings related to drug approval processes, including requirements for preclinical tests, animal studies, and formulation studies, indicating it is in early-stage development targeting oncology indications. Specific details on its mechanism of action, modality, or clinical trial status remain limited in available public sources.

Beyond the preview

Go deeper on TCB190.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCB190.

Explore the full profile